Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
306.63B
Market cap306.63B
Price-Earnings ratio
29.49
Price-Earnings ratio29.49
Dividend yield
1.99%
Dividend yield1.99%
Average volume
2.05M
Average volume2.05M
High today
$153.18
High today$153.18
Low today
$150.50
Low today$150.50
Open price
$151.54
Open price$151.54
Volume
1.60M
Volume1.60M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$123.24
52 Week low$123.24

NVS News

Reuters 51m
Novartis trims medium-term growth target, shares fall - Reuters

...

Novartis trims medium-term growth target, shares fall - Reuters
Benzinga 60m
Novartis Unveils Mid-Term Financial Guidance Backed by 35+ Potentially Submission-Enabling Pipeline Readouts

Novartis AG (NYSE:NVS) shares were down over 2% in regular trading Thursday as the company rolled forward its mid-term financial guidance to cover 2026 through...

Novartis Unveils Mid-Term Financial Guidance Backed by 35+ Potentially Submission-Enabling Pipeline Readouts
TipRanks 2h
Novartis Raises Peak-Sales Guidance for Three Key Brands

An update from Novartis ( (NVS) ) is now available. Novartis is a pure-play innovative medicines company with products and development programs across cardiova...

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
44.4%
Sell
0%

More NVS News

Seeking Alpha 4h
Novartis drops after updating mid-term outlook

Novartis drops after updating mid-term outlook Nov 19, 2026, 7:50 AM ET Novartis AG (NVS) Stock, NVSEF Stock IONS By : Dulan Lokuwithana, SA News Editor Novarti...

Novartis drops after updating mid-term outlook
TipRanks 4h
Novartis: Buy Reiterated on Strong Outlook and Pipeline Upside; $150 Price Target Unchanged

Sachin Jain, an analyst from Bank of America Securities, maintained the Buy rating on Novartis AG. The associated price target remains the same with CHF150.00....

TipRanks 5h
Novartis projects +5% cc sales CAGR through 2031

Novartis (NVS) rolled forward its mid-term guidance to 2026-2031, with net sales expected to grow at a +5% cc CAGR, and core operating income margin on track to...

The Wall Street Journal 10h
Novartis Sees Sales Growth Through 2031

Novartis also said it was on track to return to a core operating profit margin above 40% by 2029, , as previously indicated. Florence Lo / Reuters Novartis NOV...

Novartis Sees Sales Growth Through 2031
Zacks 1d
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica

Novartis (NVS Quick QuoteNVS - Free Report) announced that the FDA has approved Cosentyx (secukinumab) for treating adults with polymyalgia rheumatica (“P...

NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Benzinga 2d
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumat...

FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
Seeking Alpha 2d
Novartis' Cosentyx wins FDA approval for polymyalgia rheumatica

Novartis' Cosentyx wins FDA approval for polymyalgia rheumatica Nov 17, 2026, 7:24 AM ET Novartis AG (NVS) Stock By : Arundhati Sarkar, SA News Editor Novartis...

Novartis' Cosentyx wins FDA approval for polymyalgia rheumatica

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.